Market Overview

Notable Insider Buys This Past Week: DXC Technology, HealthEquity

Notable Insider Buys This Past Week: DXC Technology, HealthEquity
  • Insider buying can be an encouraging signal for potential investors.
  • A pair of CEOs stepped up while insider buying was slow overall.
  • Some insiders took advantage of a public offering of shares as well.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly with markets near all-time highs.

Below is a look at a couple of notable insider purchases reported in the past week, but also note that an insider bought some FedEx Corporation (NYSE: FDX) shares while others were exercising options and selling.


Healthequity Inc (NASDAQ: HQY) CEO Jon Kessler, founder Stephen Neeleman and two other directors took advantage of a public offering of shares. At $61.00 apiece, the 40,000 shares acquired altogether totaled $2.44 million. Note that two other insiders exercised options on almost 16,000 shares of this health savings accounts custodian as well.

HealthEquity recently announced the acquisition of Wageworks, a health care benefits administrator. HealthEquity's shares ended the third week of July more than 11% higher, while the S&P 500 retreated marginally. The stock closed most recently at $79.18, well above the offering purchase price. Note that shares have traded as high as $101.58 in the past 52 weeks, but the analysts' consensus price target is $89.20.

See Also: 7 Pros And Cons Of Online Banking

DXC Technology

The CEO of DXC Technology Co (NYSE: DXC), John Lawrie, stepped up and purchased more than 4,100 shares of this IT services provider last week. At prices ranging from $55.62 to $56.69 per share, that cost him more than $234,000. Note that these purchases were made pursuant to a 10b5-1 Plan and brought his stake up to almost 898,000 shares.

The company recently announced the expansion of its strategic partnership with Microsoft. The stock ended the past week at $55.93 per share, just a little higher than this chief executive's purchase range. While the consensus analyst target was last seen at $73.00, the stock has traded as high as $96.75 in the past 12 months.

Posted-In: John Lawrie Jon Kessler Stephen NeelemanNews Insider Trades


Related Articles (FDX + DXC)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Benzinga's Bulls And Bears: Apple, Boeing, Disney, Johnson & Johnson And More

Is It Possible To Be Addicted To Cannabis?